

the absence of detectable virus 24 weeks following the end of treatment. In some patients, the virus becomes undetectable by the end of treatment (end of treatment response) but then rebounds in the absence of therapy (relapse or transient response). Viral breakthrough occurs when the virus rebounds during the course of therapy. In non-responders, the virus remains detectable throughout therapy.

### Therapy for chronic HCV infection

Hepatitis C virus genotypes vary by region and susceptibility to interferon treatment [8]. Genotype 1 is the most common genotype worldwide and in Japan [8]. Weekly injections of pegylated interferon (peg-interferon) and daily oral administration of ribavirin constitute the standard therapy for genotype 1 chronic HCV [9]. However, combination therapy is costly and poorly tolerated, requires long-term treatment (48 weeks), and is successful in only 42–52 % of patients [10–12].

The success rate of HCV therapy in Japan is expected to improve greatly following the November 2011 approval of telaprevir (VX-950/MP-424; Incivek; Vertex Pharmaceuticals, Inc., Cambridge, MA, USA), the first in a class of new direct acting antiviral (DAA) drugs. Telaprevir and a related drug, boceprevir (Victrelis), were also recently approved for treatment of genotype 1 in the US, Canada, and the European Union. While boceprevir is not approved for use in Japan, a meta-analysis found no difference in outcomes between the two drugs, except for slightly higher efficacy among prior relapsers using telaprevir [13].

### Telaprevir and direct acting antiviral drugs

DAAs act by specifically inhibiting essential viral targets. Telaprevir is an NS3/4 serine protease inhibitor that mimics the carboxy-terminal region of the NS3 protease and binds slowly and tightly to the protease [14]. The NS3-4A protein is also an attractive target due to its additional role in degrading immune signaling molecules [15]. Consequently, targeting NS3-4A may not only disrupt viral replication but may also help to restore innate antiviral responses [16, 17]. However, treatment with telaprevir alone often results in a rapid decline in viral load followed by viral breakthrough due to rapid selection for resistance mutations [18, 19]. Triple therapy with peg-interferon, ribavirin, and telaprevir appears to be required to suppress viral breakthrough and achieve SVR [20].

### Telaprevir clinical trials outside of Japan

#### Phase II studies

Several phase II and III clinical trials have established the safety and efficacy of telaprevir in the treatment of HCV genotype 1 (Table 1). The PROVE I [20] and PROVE II [21] phase II studies showed SVR rates significantly higher for triple therapy compared to the standard of care (61 vs. 41 %, 69 vs. 46 %, respectively) after 12 weeks of triple therapy followed by another 12 weeks of peg-interferon plus ribavirin combination therapy. Both studies found that reducing the length of peg-interferon and ribavirin to 12 weeks erased the advantage of triple therapy over standard therapy, and PROVE II revealed that ribavirin is required to suppress viral breakthrough [20, 21]. PROVE III examined the efficacy of triple therapy in patients who failed to achieve SVR during prior interferon therapy and reported improved SVR rates among patients with prior nonresponse (39 %), relapse (69 %), or viral breakthrough (57 %) [22].

#### Phase III studies

The phase III ADVANCE study compared duration of telaprevir therapy in treatment-naïve patients using three treatment arms, a control peg-interferon plus ribavirin group and 8 and 12 week telaprevir triple therapy groups followed by response-guided peg-interferon plus ribavirin combination therapy [23] (Table 1). SVR rates were 69 % for the 8 week telaprevir treatment and 75 % for the 12 week telaprevir treatment, compared to 44 % for standard peg-interferon plus ribavirin combination therapy. The phase III REALISE study assessed response to triple therapy in patients with prior treatment failure [24]. Prior relapsers, partial responders, and null responders were randomized to a 48 week peg-interferon plus ribavirin control group or to 48 week triple therapy groups with 12 weeks of telaprevir with or without a 4 week peg-interferon plus ribavirin lead-in phase. SVR rates in the triple therapy group were 66 % with the lead-in phase and 64 % without it, compared to only 17 % in the control group. When analyzed by response to prior treatment, prior relapsers showed the strongest improvement in SVR rates, but triple therapy also appears to benefit prior null and partial responders as well [24–26]. Based on these studies, the U.S. Food and Drug Administration (FDA) approved response-guided therapy (RGT) for prior relapsers who achieved extended rapid virological response (eRVR) [27]. This allows prior relapsers to discontinue all treatment after 24 weeks if HCV RNA is undetectable at weeks 4 and 12. In Japan, duration of triple therapy is 24 weeks without regard for response to prior treatment.

**Table 1** Summary of telaprevir clinical trials

Study	Design	Results
PROVE I McHutchison et al. [20]	Phase II; <i>N</i> = 233 T12PR24: 12 week TVR + 24 week PR T12P48: 12 week TVR + 24 week PR PR48: 12 week placebo + 48 week PR	SVR PR: 41 % T12PR24: 61 % T12P48: 67 %
PROVE II Hezode et al. [21]	Phase II; <i>N</i> = 334 T12PR24: 12 week TVR + 24 week PR PR48: 12 week placebo + 48 week PR	SVR PR48: 46 % T12PR24: 69 %
PROVE III McHutchison et al. [22]	Phase II; <i>N</i> = 465 Patients with prior PR treatment failure T12PR24: 12 week TVR + 24 week PR T24PR48: 12 week TVR + 24 week PR T24P24: 12 week TVR + 24 week PR PR48: 12 week placebo + 48 week PR	SVR T12PR24: 51 % T24PR48: 53 % T24P24: 24 % PR48: 14 %
ADVANCE Jacobson et al. [23]	Phase III double-blind; <i>N</i> = 1088 Treatment-naïve patients T8PR: 8 week TVR + 24 or 48 week PR RGT T12PR: 12 week TVR + 24 or 48 week PR RGT PR: 12 week placebo + 48 week PR	SVR T8PR: 69 % T12PR: 75 % PR: 44 %
ILLUMINATE Sherman et al. [55]	Phase III open-label; <i>N</i> = 540 Treatment-naïve patients T12PR24: 12 week TVR + 24 or 48 week PR RTG T12PR48: 12 week TVR + 48 week PR	SVR T12PR24: 92 % T12PR48: 88 %
REALIZE Zeuzem et al. [24]	Phase III; <i>N</i> = 662 Patients with prior PR treatment failure T12PR48: 8 week TVR + 48 week PR Lead-in T12PR48: 4 week PR + 8 week TVR + 48 week PR PR48: 12 week placebo + 48 week PR	SVR by treatment T12P48: 64 % Lead-in T12P48: 66 % PR48: 17 % SVR by prior history Relapsers: 83–88 % Partial responders: 54–58 % Non-responders: 29–33 %
Yamada et al. [32]	Phase Ib; <i>N</i> = 10 Treatment-naïve Japanese patients TVR monotherapy: 12 week	ETR: 10 %
Ozeki et al. [19]	Phase IIa; <i>N</i> = 4; single-arm, open label Older female Japanese patients with prior PR treatment failure TVR monotherapy: 24 week + off-study PR	SVR (off-study): 100 %
Toyota et al. [33]	Phase II; <i>N</i> = 15; single-arm, open-label Treatment-naïve Japanese patients TVR monotherapy: 24 week	SVR: 7 %
Kumada et al. [28]	Phase III; <i>N</i> = 189 Treatment-naïve Japanese patients TR12P24: 12 week TVR + 12 week PR P48: 48 week PR	SVR TR12P24: 73 % P48: 49 %

**Table 1** continued

Study	Design	Results
Hayashi et al. [31]	Phase III; <i>N</i> = 141 Patients with prior PR treatment failure TR12P24: 12 week TVR + 12 week PR P48: 48 week PR	SVR Relapsers: 88 % PR48: 34 %

TVR telaprevir, PR peg-interferon plus ribavirin combination therapy, RGT response-guided therapy—24 week PR if undetectable HCV RNA at weeks 4 and 12 (eRVR); otherwise 48 week PR, ETR end-of-treatment response

### Clinical trials of telaprevir in Japan

#### Triple therapy in treatment-naïve patients

Although Asians are under-represented in the above studies (1–2 %), several phase II and III clinical trials have also been performed in Japan (Table 1). In Kumada et al. [28], 126 patients were randomly assigned to 12 weeks of telaprevir triple therapy followed by 12 weeks of combination therapy, and 63 patients were assigned to 48 weeks of combination therapy. Early viral dynamics varied greatly between the two groups, with more rapid and extensive loss of HCV RNA and a significantly higher rate of SVR in the triple therapy group (73.0 vs. 49.2 %). Rates of viral breakthrough and relapse did not differ between the treatment groups. However, patients who underwent triple therapy experienced a significantly higher incidence of side effects during the telaprevir phase of the treatment. Because HCV patients in Japan tend to be more than 10 years older than patients in Western countries and include a higher proportion of women, ribavirin-induced anemia is of particular concern [29]. Moderate or severe anemia developed in 38.1 % of patients in the triple therapy group compared to 17.5 % in the combination therapy group [30]. The ribavirin dose was adjusted accordingly, resulting in a lower total ribavirin dose in the triple therapy group. However, ribavirin dose reduction did not significantly impact treatment efficacy. Skin disorders were about twice as common in triple therapy patients (46.8 vs. 23.8 %), and severe skin lesions were only observed in this group. Due to the higher SVR rate and shorter duration of triple therapy, the study authors recommend triple therapy over combination therapy for treatment of HCV genotype 1 in Japan but stress the need for careful monitoring of hemoglobin levels and close coordination with a dermatologist.

#### Triple therapy in patients with prior treatment failure

In a second phase III clinical trial in Japan, Hayashi et al. [31] examined the safety and efficacy of triple therapy for difficult-to-treat patients who either relapsed (109) or failed

to respond to prior interferon therapy (32). As in the previous studies, patients were treated to 12 weeks of triple therapy followed by 12 weeks of combination therapy. SVR rates were 88.1 % for prior relapsers and 34.4 % for prior non-responders. Adverse events were common but moderate. 82 % of patients experienced rash or other skin disorders, mainly during the telaprevir phase, and nearly all (98.6 %) patients required ribavirin dose reduction for anemia, although ribavirin dose reduction had no effect on SVR rate down to about 20 % of the planned dose. Telaprevir was discontinued in 21.3 % of patients, and all drugs were discontinued in 16.3 % of patients. SVR rates in prior relapsers were significantly higher among men than women (93.9 vs. 79.1 %), but there was no difference among prior non-responders. Rates of viral breakthrough (18.8 %) and relapse (40.6 %) were significantly higher among prior non-responders and were more common after completion of the telaprevir phase, suggesting that extension of telaprevir therapy past 12 weeks or continuation of combination therapy past 24 weeks may improve response for prior non-responders. The study authors recommend weekly hemoglobin monitoring and note that even sharp reductions in ribavirin dose may allow therapy to continue without adversely affecting outcome.

#### Side effects of telaprevir in clinical trials in Japan

An early phase Ib study was conducted in Japan to examine the safety, tolerability, and antiviral profile of telaprevir monotherapy over 12 weeks in 10 treatment-naïve patients with high viral loads of genotype 1b [32]. Telaprevir was well tolerated and no serious adverse events occurred, but 80 % of patients developed a rash and 70 % experienced anemia. Telaprevir monotherapy demonstrated potent antiviral activity, with HCV RNA levels decreasing by 2.3 log<sub>10</sub> by 16 h and by 5.2 log<sub>10</sub> after 2 weeks. HCV RNA dropped to the limit of detection or became undetectable in all patients during the course of therapy, but only one patient achieved an end-of-treatment response. Viral breakthrough occurred in 8 patients, mainly due to Ala156 mutation. However, resistance mutants reverted to wild type during the 24 week follow-up period.

Another study examined safety and efficacy of telaprevir monotherapy over a longer duration of 24 weeks with a larger number of patients and a greater range of viral loads [33]. The only patient who achieved SVR also had the lowest baseline viral load ( $3.55 \log_{10}$  IU/ml), but three other patients were able to achieve an end-of-treatment response. HCV RNA levels decreased rapidly (average  $-5 \log_{10}$  IU/ml), and HCV RNA became undetectable in 5 patients within 8 weeks. 10 out of 15 patients (66 %) discontinued the drug due to viral breakthrough, adverse events, or other causes. Incidence of adverse events was high (14/15 patients) and 7 out of 15 patients (47 %) developed anemia, but most incidences were mild to moderate, and anemia did not lead to discontinuation of therapy. T54A and A156V variants were the most common and were not detectable at earlier time points. Secondary substitutions at V158I and I132L were also observed.

SVR rates tend to be lower among women than men over 50 in Japan (53 vs. 22 %), and dose reductions and discontinuation of treatment in standard therapy are high in this group [34]. Ozeki et al. [19] examined 24 weeks of telaprevir monotherapy in a group of four older female patients predicted to be difficult to treat due to age, sex, and Core70 and ISDR substitutions. All patients required telaprevir dose reduction due to anemia but did not require discontinuation. Resistance variants were detected in three patients, and two patients experienced viral breakthrough. Additional substitutions and variants emerged as therapy progressed. However, at the end of the telaprevir administration, all four patients were given at least 48 weeks of standard therapy, and all patients were able to achieve SVR. Although this approach results in longer duration of therapy, it avoids the need for simultaneous administration of the three drugs and takes advantage of the fact that resistance mutants selected during telaprevir therapy often have reduced fitness compared to the wild type and are more susceptible to standard therapy.

### Telaprevir antiviral resistance

Pre-existence of resistance mutations and selection for resistance may be an inevitable consequence of DAA therapy [35]. The high replication rate of HCV high ( $10^{12}$  viruses per day) coupled with the low fidelity of HCV polymerase results in a high mutation rate ( $10^{-3}$ – $10^{-5}$  per day) and the presence of viral quasispecies. Single and double substitutions from the consensus sequence are expected to exist at low frequency prior to therapy. The relative proportion of these variants increases rapidly in the viral population as the wild-type virus is eradicated. De novo mutations appear to play only a minor role in the emergence of resistance mutations, suggesting that a

genetic barrier of three to four mutations might be sufficient to reduce selection based on pre-existing mutants. At the same time, mutations conferring resistance often have reduced fitness and may require compensatory mutations in order to compete with wild-type viruses. Nonetheless, HCV sub-genotypes vary substantially in sequence, and some are likely to have a reduced genetic barrier against certain DAAs. For example, viral genotypes 1a and 1b already have different genetic barriers to telaprevir resistance; amino acid substitution of amino acid 155 requires only one nucleotide change in genotype 1a, whereas genotype 1b requires two nucleotide substitutions [36, 37]. Resistance substitutions at six major sites within the NS3 HCV protease have been reported, including at amino acids 36, 54, 155, 156, 168, and 170, and some substitutions are known to act synergistically [35]. At least 50 direct-acting antiviral drugs are at some stage of development, but these belong to a small number of distinct drug classes, increasing the risk of cross-resistance. Although wild-type strains are typically restored following removal of the drug due to viral breakthrough, prior treatment experience with DAAs, especially in high-risk sub-populations such as injection drug users, may increase the risk of transferring partially resistant strains during new infections.

### Patient selection and predictive factors for triple therapy

Telaprevir triple therapy is an extension of peg-interferon plus ribavirin combination therapy. Therefore, factors that predict the outcome of combination therapy might also help to predict outcome of triple therapy. Age, fibrosis, obesity, hepatic steatosis [38], LDL cholesterol, gamma-GTP [39], insulin resistance [40], baseline viral titer [38, 41], and IL28B SNP genotype [42–44] are known to affect response to combination therapy. HCV genotype [41] and genetic variants within the viral genome, including amino acid substitutions at positions 70 (Core70) and 91 (Core91) of the HCV core protein and substitutions within the NS5A interferon sensitivity determining region (ISDR) [45, 46], are also thought to influence response to combination therapy. Akuta et al. [47] reported that Core70 substitution and partial response to prior therapy were significant predictors of SVR for triple therapy, and partial response and alpha-fetoprotein levels were significant predictors of end-of-treatment response. Chayama et al. [26] reported that IL28B SNP genotype, rapid virological response (RVR), and response to prior therapy were predictive of outcome of triple therapy. Prior relapsers achieved high levels of SVR (93 %), whereas patients who failed to respond to combination therapy were also less likely to respond to triple therapy. ITPA SNP genotype did

not influence outcome of therapy, but patients with the anemia-susceptible ITPA SNP rs1127354 genotype typically required ribavirin dose reduction earlier than patients with other genotypes. Predictive factors for SVR identified during the ADVANCE phase III clinical trial include race, viral load, IL28B, RVR, and stage of fibrosis [48]. IL28B and on-treatment factors such as RVR appear to remain important predictors for response to triple therapy and may aid in patient selection and determination of treatment duration [48].

### 2012 guidelines for treatment of patients with chronic hepatitis C

Two guidelines for treatment of chronic HCV are available in Japan, both providing recommendations for patient selection for telaprevir triple therapy. Triple therapy in Japan consists of 12 weeks of telaprevir (Telavic) in combination with 24 weeks of dual peg-interferon  $\alpha$  2b (Peg-Intron) and 24 weeks of ribavirin (Rebetol).

#### Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: 2012 Guideline on Therapy for Chronic Hepatitis C

The following are the most recent guidelines from the Study Group for the Standardization of Treatment of Viral

Hepatitis Including Cirrhosis published by the Ministry of Health, Labour and Welfare of Japan (Tables 2, 3, 4, 5, 6). The recommended course of treatment differs depending on HCV genotype, viral titer, and prior history of interferon treatment. Patients with high viral load ( $>5.0$  log IU/ml) of genotype 1 are considered difficult to treat and are recommended for triple therapy in both interferon treatment-naïve and treatment-experienced patients (Tables 2, 3). In this group of patients, IL28B SNP genotype, HCV Core70 and ISDR substitutions are strong predictors of treatment outcome and may be used to determine the starting therapy. Patients with rs8099917 TT genotype are recommended for triple therapy. If telaprevir is contraindicated due to age, gender, or hemoglobin levels, peg-interferon plus ribavirin may be used instead (Table 4). However, combination therapy alone without telaprevir is not recommended for patients with rs8099917 TG/GG genotype, Core70 mutant, and wild type ISDR (0–1 substitutions) due to poor response to combination therapy in these patients (Table 4). For treatment-naïve patients with low viral loads of either genotype 1 or genotype 2, the recommended treatment is 24–48 weeks of peg-interferon  $\alpha$  2a (Pegasys) (Table 1). Recommended treatment for patients with high viral load of genotype 2 is 24 weeks of dual therapy with ribavirin and either peg-interferon  $\alpha$  2b or interferon  $\beta$  (Feron). In the case of adverse drug reactions, such as depression, or in the case of increased risk of adverse drug reactions due to age, interferon  $\beta$  plus ribavirin should be

**Table 2** Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: 2012 guidelines for chronic hepatitis C therapy for treatment-naïve patients

	Genotype 1	Genotype 2
High viral load	Peg-IFN $\alpha$ 2b: Peg-Intron (24 weeks)	Peg-IFN $\alpha$ 2b: Peg-Intron
$\geq 5.0$ log IU/mL	+Ribavirin: Rebetol (24 weeks)	+Ribavirin: Rebetol (24 weeks)
$\geq 300$ fmol/L	+Telaprevir: Telavic (12 weeks)	IFN $\beta$ : Feron
$\geq 1$ Meq/mL		+Ribavirin: Rebetol (24 weeks)
Low viral load	IFN (24 weeks)	IFN (8–24 weeks)
$< 5.0$ log IU/mL	Peg-IFN $\alpha$ 2a: Pegasys (24–48 weeks)	Peg-IFN $\alpha$ 2a: Pegasys (24–48 weeks)
$< 300$ fmol/L		
$< 1$ Meq/mL		

**Table 3** Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: 2012 guidelines for chronic hepatitis C therapy for previously treated patients

	Genotype 1	Genotype 2
High viral load		
$\geq 5.0$ Log IU/mL		
$\geq 300$ fmol/L	Peg-IFN $\alpha$ 2b + Ribavirin (24 weeks)	Peg-IFN $\alpha$ 2b + Ribavirin (36 weeks)
		OR
$\geq 1$ Meq/mL	+Telaprevir (12 weeks) combined therapy	Peg-IFN $\alpha$ 2a + Ribavirin (36 weeks)
		OR
Low viral load		IFN $\beta$ + Ribavirin (36 weeks)
$< 5.0$ log IU/mL		
$< 300$ fmol/L		
$< 1$ Meq/mL		

considered for patients, regardless of genotype 1 or 2. Previously treated patients with genotype 1 should be treated with triple therapy, consisting of 12 weeks of telaprevir and 24 weeks of peg-interferon  $\alpha$  2b and ribavirin regardless of viral load (Table 3). Patients with genotype 2 should be given 36 weeks of dual therapy with ribavirin and either peg-interferon  $\alpha$  2a/b or interferon  $\beta$  (Table 3).

Telaprevir triple therapy is associated with an increased risk of anemia, skin lesions, and other side effects compared to peg-interferon plus ribavirin dual therapy, especially among females and older patients [20, 26]. Initial dosages should be determined based on the patient’s age, weight, and expected tolerability. However, for female patients with baseline hemoglobin levels between 13 and 14 g/dl or male patients with baseline hemoglobin levels between 12 and

13 g/dl, ribavirin dosage should be reduced by 200 mg and telaprevir dosage should be reduced to 1500 mg (Table 5). Triple therapy is unsafe in patients with baseline hemoglobin levels <12 g/dl. Hemoglobin levels should be closely monitored, and in the case of anemia ribavirin, dosage should be reduced based on both the absolute value of the hemoglobin levels as well as the amount of the reduction (Table 6). Triple therapy should be conducted in cooperation with a dermatologist to manage the high risk of potentially serious skin problems, including Stevens–Johnson syndrome and drug-induced hypersensitivity syndrome. Use of all three drugs should immediately cease in the event of serious skin problems. In the event of cutaneous symptoms, adequate treatment should begin early in consultation with a dermatologist. Benefits and risks of administration of oral steroids or other drugs should be

**Table 4** Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: pretreatment indicators for triple therapy

Indications for therapy involving a host factor (IL28B) and two viral factors (ISDR and Core70) at the start of triple combined therapy including telaprevir in the initial therapy for the treatment-naïve patients with high viral load of genotype 1

1. Telaprevir triple therapy is recommended in patients homozygous for the favorable IL28B SNP allele (e.g., rs8099917 T/T genotype) because the anticipated effect of the therapy is high. If telaprevir therapy is likely to be difficult in consideration of the patient’s age, gender, hemoglobin level, or other factor, then peg-interferon  $\alpha$  or interferon  $\beta$  plus ribavirin combination therapy should be chosen instead
2. Telaprevir triple therapy may be preferred over interferon plus ribavirin combination therapy in patients with an unfavorable IL28B SNP genotype (rs8099917 T/G or G/G), wild-type ISDR (0–1 substitutions), and a Core70 mutation, because the effect of interferon plus ribavirin combination therapy is low in these patients

**Table 5** Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: guidelines for ribavirin and telaprevir dose reduction based on baseline hemoglobin levels

Baseline hemoglobin (g/dl)	Ribavirin	Telaprevir
≥14.0	Conventional dose	Conventional dose (2250 mg)
13.0–14.0	Decrease by 200 mg (females only)	Decrease to 1500 mg (females only)
12.0–13.0	Decrease by 200 mg	Decrease to 1500 mg
<12.0	Triple therapy unsafe	

Initial ribavirin and telaprevir dosages relative to hemoglobin levels are estimated based on the results of clinical trials. Initial dosages should be determined by a specialist based on the patient’s age, weight, etc

**Table 6** Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: precautions for triple therapy with peg-interferon  $\alpha$  2b, ribavirin, and telaprevir in case of high viral load of genotype 1

1. Severe anemia occurs more frequently in peg-interferon  $\alpha$  2b plus ribavirin plus telaprevir triple therapy compared to interferon plus ribavirin combination therapy. Care should be taken to monitor hemoglobin levels, and in case of anemia, ribavirin dosage should be adjusted based on consideration of both the absolute value of hemoglobin as well as the amount of hemoglobin reduction. Because the risk of anemia increases with age, peg-interferon  $\alpha$  or interferon  $\beta$  plus ribavirin combination therapy is the preferred initial therapy for older female patients or patients with low hemoglobin levels and high viral loads of genotype 1
2. Peg-interferon  $\alpha$  2b plus ribavirin plus telaprevir triple therapy should be conducted in coordination with a dermatologist because serious skin problems such as Stevens–Johnson syndrome and drug-induced hypersensitivity syndrome are likely to occur. In the event of severe skin problems, use of all three drugs should be immediately ceased. If cutaneous symptoms are expressed, adequate treatment should begin at an early date. Course of treatment should be decided in cooperation with a dermatologist in view of the respective risks and benefits, and administration of oral steroids should be considered if necessary
3. Some patients experience an increase in uric acid and creatinine levels rise during the first week of peg-interferon  $\alpha$  2b plus ribavirin plus telaprevir triple therapy. If uric acid levels become aberrant, early administration of a therapeutic agent for hyperuricemia is required


considered, if necessary. Some patients may also experience a rapid increase in uric acid levels at the start of therapy (1–7 days), in which case a therapeutic agent should be administered early to reduce hyperuricemia.

Japan Society of Hepatology: 2012 guidelines for treatment of chronic HCV


The 2012 guidelines supported by the Japan Society of Hepatology (<http://www.jsh.or.jp/english/index.html>) provide more specific recommendations for patients with high viral load of HCV genotype 1 based on factors including patient age, IL28B SNP genotype, Core70 and ISDR substitutions, prior treatment history, and stage of fibrosis. The English version of this guideline will be published soon in Hepatology Research (2012). Treatment-naïve patients with rs8099917 TT genotype should be given triple therapy, if possible, but combination therapy may be substituted if telaprevir is contraindicated (Fig. 1a). Interferon β plus ribavirin may also be substituted in case of depression. Therapy should also be postponed in patients with both the unfavorable IL28B SNP genotype (TG/GG) and Core70 mutation due to the poor expected outcome of therapy. When IL28B and Core70 data are not available, patients should be

treated with triple therapy or combination therapy, depending on tolerability and fibrosis stage (Fig. 1b). Therapy may be postponed in nonelderly patients (≤65) with mild fibrosis.

Triple therapy provides a retreatment opportunity for patients who were unable to eradicate the virus during prior therapy. However, not all patients show an improved response, and a patient’s response to the prior therapy should be used as a guide for treatment selection, if available. Patients who experienced relapse or partial response are expected to respond well to therapy and should be administered triple therapy or combination therapy depending on age and stage of fibrosis (Fig. 2a). On the other hand, patients who experienced null response during prior therapy should be administered triple therapy, if possible; otherwise, treatment should be postponed, as combination therapy alone is unlikely to be successful. When treatment history is unknown but IL28B SNP and Core70 data are available, guidelines for treatment-naïve patients should be followed (Fig. 2a). In the absence of



**Fig. 1** Japan Society of Hepatology: 2012 treatment guidelines for treatment-naïve chronic HCV patients with high viral load of genotype 1. **a** Patients with the favorable IL28B SNP genotype (rs8099917 TT) and/or wild type viral core protein amino acid 70 (Core70) should be treated with triple or combination therapy, if possible, depending on age and fibrosis stage. Patients with both the unfavorable IL28B SNP genotype (TG/GG) and Core70 substitution should postpone therapy due to poor expected outcome. **b** When IL28B SNP genotype and Core70 substitutions are unavailable, treatment is determined based on patient age and stage of fibrosis



**Fig. 2** Japan Society of Hepatology: 2012 treatment guidelines for re-treatment of previously treated chronic HCV patients with high viral load of genotype 1. **a** Patients who experienced relapse or partial response during prior interferon therapy should be treated with triple therapy or combination therapy, if possible, depending on age. Triple therapy is recommended for patients who experienced null response to prior therapy, but if triple therapy is not possible, therapy should be postponed due to poor expected response to combination therapy in these patients. **b** When prior treatment history is unavailable but IL28B SNP and core amino acid 70 (Core70) information is available, guidelines for treatment-naïve patients should be followed (Fig. 1a). When both prior treatment history and IL28B SNP and Core70 information are unavailable, triple therapy is recommended for older patients as well as for younger patients with advanced fibrosis. If fibrosis is mild, triple therapy for younger patients should be postponed

both treatment history and IL28B/Core70 data, patients should be treated with triple therapy or combination therapy, depending on tolerability and fibrosis stage (Fig. 2b).

**Future therapies**

The development, clinical testing, and approval of telaprevir triple therapy is the culmination of a decades-long process [49]. At the same time, however, the introduction of telaprevir and boceprevir represents the first success in a much broader direct antiviral strategy targeting multiple facets of the viral life cycle. Future clinical trials involving triple therapy are likely to lead to further improvements in SVR rate, shorter duration of therapy, and improved management of side effects, especially among specific patient subgroups. Future research will also identify new predictive factors associated with response to DAA therapy, including risk of viral breakthrough and adverse events.

A major goal of future clinical research, however, is to move beyond interferon-based therapy in favor of interferon-free DAA combination therapies. A number of novel DAAs are currently undergoing clinical testing (Table 7), and DAAs are being evaluated in combination with interferon as

well as other DAAs (Table 8). Many other drugs and vaccines are currently in some stage of clinical testing ([http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs\\_2012.pdf](http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs_2012.pdf)). Telaprevir and other DAAs under development are not intended for use in monotherapy due to the low genetic barrier to resistance. However, combinations of DAAs with different viral targets and mechanisms of action should have a higher genetic barrier. For example, in a chimeric mouse model a protease inhibitor (telaprevir) in combination with an RNA polymerase inhibitor (MK-0608) resulted in rapid clearance of HCV RNA without emergence of resistance mutants [50].

Several DAA combination therapies have entered phase II clinical trials in humans. Safety and efficacy of dual therapy with daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) was examined in two phase II clinical trials in the US and Japan for difficult-to-treat genotype 1 patients with null response to prior interferon therapy [51–53]. The studies differed notably with respect to sub-genotype; 81 % of patients in the US study had genotype 1a, whereas all patients in the Japanese study had genotype 1b. In the Japanese study, 77 % of patients achieved SVR (90 % in the sentinel cohort) [52, 53], whereas in the dual DAA therapy arm of the US study (group A), only 36 % of

**Table 7** Direct-acting antiviral (DAA) drugs in clinical testing

	Phase I	Phase II	Phase III	Phase IV
Protease inhibitor	ACH-2684	ABT-450 ACH-1625 BMS-650032 BMS-791325 GS-9256 MK-5172 MK-7009 RG7227	BI201335 TMC435	Telaprevir
Polymerase inhibitor	ALS-2158 ALS-2200 ABT-072 ABT-333 MK-3281 TMC649128	ANA598 BI207127 Filibuvir GS-9190 IDX184 INX-189 GS-938 RG7128 VX-222 VX-759	GS-7977	
NS5A inhibitor	ACH-2928 AZD-7295 IDX719 PPI-461 PPI-688		BMS-790052	
NS4B inhibitor	Clemizole			
Entry inhibitor	ITX-5061			



**Table 8** Direct-acting antiviral (DAA) combination therapies in clinical testing

Usage	Phase II	Phase III	Phase IV
DAA combinations	ABT-450 + ABT-072 ABT-450/r + ABT-267 <sup>a</sup> ABT-450 + ABT-333 BI201335 + BI207127 BMS-790052 + GS-7977 BMS-790052 + TMC435 Boceprevir + mericitabine GS-9256 + GS-9190 GS-7977 + TMC435 RG7128 + RG7227 Telaprevir + VX-222	BMS-790052 + BMS-650032 <sup>a</sup>	
DAA + IFN		Peg + RBV + BI201335 Peg + RBV + BMS-790052 Peg + RBV + GS-7977 Peg + RBV + TMC435 <sup>b</sup> Peg + RBV + MK-7009 <sup>b</sup> IFN $\lambda$ + RBV + BMS-790052 <sup>a</sup> IFN $\lambda$ + RBV + BMS-650032 <sup>a</sup>	Peg + RBV + telaprevir <sup>b</sup>

DAA combinations, interferon-free combination therapies involving two or more DAAs; DAA + IFN, therapies based on interferon plus ribavirin combination with one or more DAAs; Peg, pegylated interferon, RBV, ribavirin; IFN, interferon; IFN  $\lambda$ , interferon-lambda (type III interferon)

<sup>a</sup> Currently in clinical trials in Japan

<sup>b</sup> Completed clinical trials in Japan

patients achieved SVR, while the other patients either relapsed or had viral breakthrough [51]. In the latter study, the two patients with genotype 1b both achieved SVR. All patients in group B, in which all patients received peg-interferon plus ribavirin in addition to daclatasvir and asunaprevir, achieved SVR at 12 weeks after treatment. These discrepancies may reflect differences between genotypes 1a and 1b in the genetic barrier for resistance to this drug combination [51] and suggest that such treatments may be more amenable in Japan where genotype 1b is common.

In another phase II dual DAA therapy study, treatment-naive genotype 1 patients were administered GS-9256, an NS3 serine protease inhibitor, and tegobuvir (GS-9190), a non-nucleoside NS5B polymerase inhibitor, with or without peg-interferon and ribavirin, followed by standard therapy with peg-interferon plus ribavirin [54]. Only 7 % of patients receiving dual DAA therapy alone achieved RVR, whereas RVR rates increased to between 67 and 100 % among patients who also received peg-interferon and/or ribavirin. Although promising, these studies suggest that interferon and ribavirin will continue to be used in future DAA combination therapies to control viral breakthrough.

### Future perspective and conclusion

Although SVR rates still fall far short of 100 %, the recent introduction of telaprevir to standard peg-interferon plus

ribavirin therapy greatly increases the chance that a patient with chronic HCV infection will be able to successfully clear the virus, and it offers a promising retreatment opportunity for patients who were unable to clear the virus in previous therapy attempts. Despite the higher SVR rate, however, triple therapy also further limits patient eligibility and increases the burden on patients. This issue is of particular concern in Japan where patients tend to be older than in Western countries and at greater risk for HCC, as well as more likely to face complications or treatment discontinuation due to adverse events.

**Acknowledgments** This work was supported in part by Grants-in-Aid for scientific research and development from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare, Government of Japan.

**Conflict of interest** The author declares that he has nothing to disclose regarding funding or conflict of interest with respect to this manuscript.

### References

1. Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. *Intervirology*. 1994;37:68–76.
2. Lavanchy D. The global burden of hepatitis C. *Liver Int*. 2009;29(Suppl 1):74–81.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. *Liver Transpl*. 2003;9:331–8.

4. Alter MJ. Epidemiology of hepatitis C in the West. *Semin Liver Dis.* 1995;15:5–14.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis.* 2005;5:558–67.
6. Hoofnagle JH. Course and outcome of hepatitis C. *Hepatology.* 2002;36:S21–9.
7. Seeff LB. Natural history of chronic hepatitis C. *Hepatology.* 2002;36:S35–46.
8. Chayama K, Hayes CN. Hepatitis C virus: how genetic variability affects pathobiology of disease. *J Gastroenterol Hepatol.* 2011; 26:83–95.
9. Kumada H, Okanou T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. *Hepatol Res.* 2010; 40:8–13.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med.* 2004;140:346–55.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet.* 2001;358:958–65.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med.* 2002;347:975–82.
13. Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S. The relative efficacy of boceprevir and telaprevir in the treatment of HCV Genotype 1. *Clin Infect Dis.* 2012. doi:10.1093/cid/cis880
14. Perni RB, Almqvist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. *Antimicrob Agents Chemother.* 2006;50:899–909.
15. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science.* 2003; 300:1145–8.
16. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology.* 2006; 131:997–1002.
17. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology.* 2007;132: 1767–77.
18. Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. *Hepatology.* 2011;54:781–8.
19. Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. *J Gastroenterol.* 2011;46:929–37.
20. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med.* 2009;360:1827–38.
21. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med.* 2009;360:1839–50.
22. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med.* 2010;362:1292–303.
23. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 2011;364:2405–16.
24. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. *New Engl J Med.* 2011;364:2417–28.
25. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. *Aliment Pharmacol Ther.* 2012;35:647–62.
26. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. *J Infect Dis.* 2011;204:84–93.
27. Liu J, Jadhav PR, Amur S, et al. Response guided telaprevir therapy in prior relapsers?: the role of bridging data from treatment-naive and experienced subjects. *Hepatology.* 2012. doi:10.1002/hep.25764
28. Kumada H, Toyota J, Okanou T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. *J Hepatol.* 2012;56:78–84.
29. Chayama K, Hayes CN, Yoshioka K, et al. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. *Hepatol Res.* 2010;40:1155–67.
30. Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. *Intervirology.* 2006;49:7–17.
31. Hayashi N, Okanou T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. *J Viral Hepat.* 2012;19:e134–42.
32. Yamada I, Suzuki F, Kamiya N, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. *J Viral Hepat.* 2012;19:e112–9.
33. Toyota J, Ozeki I, Karino Y, et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. *J Viral Hepat.* 2012.
34. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. *Dig Dis Sci.* 2009;54:1317–24.
35. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. *J Hepatol.* 2011;55:192–206.
36. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. *Hepatology.* 2007;46:631–9.
37. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. *Hepatology.* 2008;48:1769–78.
38. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterology.* 2006;130:231–64 (quiz 214–7).
39. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol.* 2007;46:403–10.
40. Romero-Gómez M, Del Mar Viloria M, Andrade R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology.* 2005;128:636–41.
41. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. *Hepatology.* 1996;24:1003–9.
42. Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature.* 2009;461:399–401.

43. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet.* 2009; 41:1100–4.
44. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature.* 2009;461:798–801.
45. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology.* 2005;48:372–80.
46. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b—sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. *J Clin Invest.* 1995;96:224–30.
47. Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. *J Med Virol.* 2012;84:1097–105.
48. Kwo PY. Phase III results in genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. *Liver Int.* 2012;32(Suppl 1):39–43.
49. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. *Nat Biotechnol.* 2011;29:993–1003.
50. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. *J Hepatol.* 2011; 54:872–8.
51. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. *N Engl J Med.* 2012;366:216–24.
52. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the non-structural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology.* 2012;55: 742–8.
53. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon. In: 47th annual meeting of the European Association for the study of the liver (EASL 2012). Barcelona, 2012; Abstract 14.
54. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. *Hepatology.* 2012;55:749–58.
55. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med.* 2011;365:1014–24.

## Review Article

Impact of interleukin-28B genotype on *in vitro* and *in vivo* systems of hepatitis C virus replicationKazuaki Chayama,<sup>1,2,3</sup> C. Nelson Hayes<sup>1,2,3</sup> and Michio Imamura<sup>1,2,3</sup>

<sup>1</sup>Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, <sup>2</sup>Liver Research Project Center, Hiroshima University, <sup>3</sup>Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima, Japan

Identification of the relationship between the interleukin (IL)-28B genotype and the effect of peginterferon plus ribavirin treatment has had a great impact on the study of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection. Differential expression levels of interferon-stimulated genes (ISG) in the liver and white blood cells based on the *IL-28B* genotype, which may in turn lead to differences in outcome of therapy, indicate that previous studies should be re-evaluated taking the effect of the *IL-28B* single nucleotide polymorphism (SNP) into consideration, although the exact mechanism of how variation in *IL-28B* SNPs affect HCV eradication remains unknown. These results suggest that the genotypes of multiple cell types, including liver and immune cells, contribute to the efficacy of therapy. Studies using human hepatocyte chimeric mice, in which effector cells of the human adaptive immune response are

absent, showed that viral load, ISG expression levels and reduction of HCV RNA by interferon are affected by the *IL-28B* genotype. Genetic differences among hepatocytes may, therefore, contribute to differences in baseline viral loads and response to interferon therapy. Further studies should be done to clarify the mechanism of action of *IL-28B* SNP on viral load and effect of interferon treatment. Advances in cell culture systems and human hepatocyte chimeric mice, as well as upcoming *in vitro* and *in vivo* experimental systems, provide an effective platform to examine the effects of host and viral genetic variation on infection and response to interferon.

**Key words:** cell culture, chimeric mouse, interferon-stimulated genes,  $\lambda$ -interferon, single nucleotide polymorphism

## INTRODUCTION

IN 2002, INTERFERON (IFN)- $\lambda$ 1, - $\lambda$ 2 and - $\lambda$ 3, also known as interleukin (IL)-29, IL-28A and *IL-28B*, respectively, were identified as members of a new family of IFN (type III) with antiviral activity.<sup>1–7</sup> In 2009, an association between single nucleotide polymorphism (SNP) genotypes within the *IL-28B* locus and the efficacy of peginterferon plus ribavirin combination therapy was established in a series of landmark

genome-wide association studies.<sup>8–12</sup> Ge *et al.* published the first report of an association between the rs12979860 polymorphism and sustained virological response (SVR) following 48 weeks of combination therapy in a large cohort of patients of European or African-American ancestry with genotype 1.<sup>8</sup> This report was followed by studies based on rs8099917 by Tanaka *et al.* and Suppiah *et al.* in 314 Japanese and 848 Australian patients, respectively.<sup>9,10</sup> While the association was initially identified in patients with genotype 1,<sup>8–11</sup> these findings have since been replicated in other hepatitis C virus (HCV) genotypes, although the effect of the SNP appears to be weaker in genotypes 2 and 3.<sup>13–19</sup> Although most studies have focused on combination therapy, Ochi *et al.* showed that the *IL-28B* SNP is also associated with outcome of IFN monotherapy.<sup>12</sup> Although only 20–30% of patients are typically able to resolve acute HCV infection without treatment, Thomas *et al.* showed a strong association between rs12979860 genotype and spontaneous resolution of acute HCV

Correspondence: Professor Kazuaki Chayama, Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate school of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Email: chayama@hiroshima-u.ac.jp

Financial disclosure: The authors declare that they have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.

Received 9 February 2012; revision 11 March 2012; accepted 11 March 2012.

infection in 1008 individuals of European and African ancestry.<sup>20</sup> Tillmann *et al.* also observed a higher frequency of spontaneous clearance in patients with the rs12979860 CC genotype in a cohort of 190 German women.<sup>21</sup> These results suggest that the *IL-28B* SNP is robustly associated with resolution of HCV infection and response to IFN therapy across a range of viral genotypes.

### IN VITRO REPLICATION OF HCV USING CELL LINES

DEVELOPMENT OF EFFECTIVE therapies for HCV ultimately requires establishing a host cell able to support infection, as well as a virus capable of replicating in this environment.<sup>22</sup> However, HCV propagates poorly in cultured cells, and each step towards development of an infection system has been hampered by challenges. A major step forward involved transfection of the human hepatoma cell line Huh-7 using a viral clone.<sup>23</sup> This system was subsequently improved using permissive cell lines based on cell-culture adaptive mutations, such as Huh-7.5, which contains a point mutation in the retinoic acid-inducible gene (*RIG-1*).<sup>24,25</sup> The need for cell culture adaptive mutations was overcome using JFH-1, an HCV viral genome isolated from a patient with fulminant hepatitis.<sup>26</sup> High infection and replication rates were later achieved using the combination of JFH-1 and the highly permissive Huh-7.5.1 cell line.<sup>24</sup>

Although HCV can be propagated efficiently in hepatoma cells, these cells have a number of abnormalities<sup>27</sup> limiting their suitability and accuracy as a model of infection and host responses. However, other options are now available, such as micropatterned co-cultures (MPCC), in which primary human hepatocytes can be maintained in a multiwell format.<sup>28</sup> This system makes it possible to support the entire HCV life cycle and provides a high-throughput method for assessing efficacy and toxicity of therapeutic drugs.<sup>28</sup> Another recent advancement was the addition of miR-122 and a HCV receptor to hepatocellular carcinoma-derived HepG2 cells, resulting in efficient viral entry and replication.<sup>29</sup> Hepatic stem cells may offer another approach to examining the relationship between *IL-28B* on HCV infection in cell culture.

### EVALUATION OF EFFECT OF IFN- $\lambda$ IN CELL CULTURE

AS SHOWN IN Table 1, the effect of IFN- $\lambda$  had been evaluated using a number of human and animal cell models even before the identification of the associa-

tion between *IL-28B* SNP and outcome of combination therapy. IFN- $\lambda$  has been investigated in over 100 cell lines in 50 different tissue types representing several different species, including humans, mice, Chinese hamsters and African green monkeys. Following the identification of the role of *IL-28B* in response to therapy, particular attention has been paid to the effect of IFN- $\lambda$  in human and mouse hepatocytes.

The high odds ratios of SVR in patients with eradication-favorable *IL-28B* genotypes suggest that cells obtained from donors with different *IL-28B* genotypes might respond differently to IFN. To prevent potential confounding and improve comparability among studies, the *IL-28B* genotype of cell culture systems should be evaluated. A recent letter by Bensadoun *et al.* noted that Huh7-derived cell lines may differ in the *IL-28B* genotype even though they originated from a common ancestor.<sup>44</sup> They analyzed *IL-28B* genotype frequencies among Huh7 cell lines using ultra-deep pyrosequencing and showed that one Huh7 cell line was fixed for the eradication-unfavorable rs12979860 TT genotype, whereas descendants in the HCV-permissive replicon Huh7.5.1 line were fixed for the favorable CC genotype, perhaps due to the polyploid nature of hepatoma cells and selection of specific clones from ancestral polyclonal populations. Therefore, it may be helpful to characterize the genetics of hepatoma cell lines used in HCV research.<sup>44</sup> Nonetheless, hepatoma cell lines have many abnormalities that limit extrapolation of results, and the role of the *IL-28B* SNP may have more or less relevance in a particular cell line.

### IN VIVO REPLICATION OF HCV USING HUMAN HEPATOCYTE CHIMERIC MOUSE

HEPATITIS C VIRUS is only able to infect and effectively proliferate in human and chimpanzee hepatocytes. A breakthrough in HCV research occurred when the first small animal model of HCV infection was reported by Mercer *et al.*<sup>45</sup> They transplanted human liver cells into urokinase-type plasminogen activator severe combined immunodeficiency mice to create chimeric mice with human hepatocytes. As it is still difficult to culture human hepatocytes, the chimeric mouse model is ideal to study the nature of liver cells. Liver cells implanted into an individual mouse are usually transplanted from a single donor, and chromosomal alterations seen in cancer cell lines are expected to be rare or absent in this non-tumor liver cell proliferation system. Tateno *et al.* improved the repopulation rate of human liver cells in the mouse liver,<sup>46</sup> which was

**Table 1** Human and animal cell models

Author	Cell lines	Species	Tissue	Description
Kotenko <i>et al.</i> <sup>30</sup>	COS-1	Monkey, African green	Kidney	SV40 transformed African green monkey kidney
	HT29	Human	Colon	Adenocarcinoma
	16-9	Hamster-human hybrid		Hamster-human somatic cell hybrid line
	CHO-K1	Chinese hamster	Ovary	Subclone of CHO cells
	CV-1	African green monkey	Kidney	Kidney, highly susceptible to SV40 infection
	HeLa S3	Human	Uterine cervix	Cervical epithelioid carcinoma
	A549	Human	Lung	Adenocarcinoma
	HaCaT	Human	Keratinocyte	
	HuH7	Human	Liver	Hepatoma, differentiated
	Raji	Human	Lymphocyte	Lymphoma, Burkitt's
	MOLT-4	Human	Lymphocyte	Leukemia, acute T lymphoblastic
	HL60	Human	Lymphocyte	Leukemia, acute promyelocytic, differentiation-inducible
	K562	Human	Lymphocyte	Leukemia, chronic myelogenous, differentiation-inducible
	SW480	Human	Colon	Adenocarcinoma
	G-361	Human	Melanoma	Malignant melanoma, skin
	Sheppard <i>et al.</i> <sup>7</sup>	sf9	<i>Spodoptera frugiperda</i>	<i>Spodoptera frugiperda</i>
Blood mononuclear cells		Human	Peripheral blood mononuclear cells	
COS-7		Monkey, African green	Kidney	Transformant of CV-1 cells by origin-defective SV-40, SV-40 large T-antigen-expressing
293 HEK		Human	Kidney	Transformed embryonic kidney by adenovirus (type 5)
HepG2		Human	Liver	Hepatoma
HL60		Human	Lymphocyte	Leukemia, acute promyelocytic, differentiation-inducible
HeLa S3		Human	Uterine cervix	Cervical epithelioid carcinoma
K562		Human	Lymphocyte	Leukemia, chronic myelogenous, differentiation-inducible
MOLT-4		Human	Lymphocyte	Leukemia, acute T lymphoblastic
Raji		Human	Lymphocyte	Lymphoma, Burkitt's
SW480		Human	Colon adenocarcinoma cell	
A549		Human	Lung (cancer)	Adenocarcinoma
G-361	Human	Melanoma	Malignant melanoma, skin	

Table 1 Continued

Author	Cell lines	Species	Tissue	Description
Donnelly <i>et al.</i> <sup>31</sup>	A-431	Human	Epidermoid carcinoma	Epidermoid carcinoma, high expression of epidermal growth factor receptor
	COLO-205	Human	Colon	Adenocarcinoma
	Primary human hepatocytes	Human	Primary human hepatocytes	
	HT-29 COS-7	Human Monkey, African green	Colon Kidney	Adenocarcinoma Transformant of CV-1 cells by origin-defective SV-40, SV-40 large T-antigen-expressing
Dumoutier <i>et al.</i> <sup>32</sup>	BW5147	Mouse	Hemolymphocytic	Lymphoma, T-cell lymphoma (AKR/J mouse)
	HEK293-EBNA	Human	Kidney	Transformed embryonic kidney by adenovirus (type5)
	HEK293	Human	Kidney	Transformed embryonic kidney by adenovirus (type 5)
Brand <i>et al.</i> <sup>3</sup>	P815	Mouse	Hemolymphocytic	Mastocytoma (DBA/2 mouse)
	BWLICR2	Mouse	Thymus	Thymoma
	Caco-2	Human	Colon	Colorectal cancer-derived cell
	DLD-1	Human	Colon	Colorectal cancer-derived cell
	SW480	Human	Colon	Colorectal cancer-derived cell
	HCT116	Human	Colon	Colorectal cancer-derived cell
	HT-29	Human	Colon	Colorectal cancer-derived cell
	CCL-6	Human	Colon	Normal colonic tissue and the untransformed cell
Brand <i>et al.</i> <sup>33</sup>	LNCaP	Human	Prostate adenocarcinoma cell	
	Int-407	Human	Colon	Fetal colon
	HepG2	Human	Liver	Hepatoma
	Hep3B	Human	Liver	Hepatoma
	HuH-7	Human	Liver	Hepatoma

Meager <i>et al.</i> <sup>6</sup>	U-87MG	Human	Glia	Glioblastoma
	U-138MG	Human	Glia	Glioblastoma
	U-373MG	Human	Glia	Glioblastoma
	MO-G-UIVW	Human	Glia	Glioblastoma
	CCF-STTG1	Human	Glia	Glioblastoma
	MO-G-CCM	Human	Glia	Glioblastoma
	1321NI	Human	Glia	Glioblastoma
	LN229	Human	Glia	Glioblastoma
	LN319	Human	Glia	Glioblastoma
	LN443	Human	Glia	Glioblastoma
	2D9	Human	Glia	Glioblastoma
	SW480	Human	Bladder	Bladder carcinoma
	T24/83	Human	Bladder	Bladder carcinoma
	PANC-1	Human	Pancreas	Pancreatic carcinoma
	MIA-PA-CA-2	Human	Pancreas	Pancreatic carcinoma
	MG63	Human	Bone	Osteosarcoma cell
	TE671	Human	Cerebellum	Medulloblastoma
	HT1080	Human	Fibrocyte	Fibrosarcoma
	WISH	Human	Amniotic cell	
	RT4	Human	Bladder	Bladder carcinoma
	HepG2	Human	Bladder	Bladder carcinoma
	U1C	Human	Fibrocyte	Fibrosarcoma
	A549	Human	Lung	Adenocarcinoma
	HEK 293	Human	Kidney	Transformed embryonic kidney by adenovirus (type 5)
	Daudi	Human	Lymphocyte	Lymphoma, Burkitt's
	MRC-5	Human	Fibroblast	Normal diploid fibroblast
	HEF	Human	Fibroblast	Normal diploid fibroblast cell
Hep2C	Human	Cervix	Laryngeal carcinoma	
KD4	Human	Muscle	Rhabdomyosarcoma	
L-929	Mouse	Adipose tissue	Fibrosarcoma	
L-M	Mouse	Adipose tissue	Fibrosarcoma	
MEG-01 s	Human	Myeloid cell	Chronic myelogenous leukemia cell	
TF-1	Human	Erythrocyte	Erythroleukemia	
MEG-01	Human	Lymphocyte	Lymphocytic leukemia	
93D7	Human	Lung	Adenocarcinoma	
A549	Human	lung	Adenocarcinoma	
CRL-2407	Human	Lymphocyte	Activated natural killer cell	
NK and T cells	Human	Lymphocytes		
Siren <i>et al.</i> <sup>34</sup>				



Table 1 Continued

Author	Cell lines	Species	Tissue	Description
Doyle <i>et al.</i> <sup>4</sup>	HepG2-WT10	Human	Liver	Hepatoma
	AVA5	Human	Liver	HCV replicon derived from Huh7
	HuH7	Human	Liver	Hepatoma
	SK-Hep-1	Human	Liver	The non-hepatocyte liver-derived cells
	HepSMCV	Human	Liver	Hepatic vein smooth muscle cells
	HepSMCA	Human	Liver	Hepatic artery smooth muscle cells
	HepFIB	Human	Liver	Hepatic fibroblasts
	HuHep	Human	Liver	Hepatoma
	U266	Human	B-cell	Myeloma
Mennechet <i>et al.</i> <sup>35</sup>	T cells	Human	Peripheral blood mononuclear cells	
Ank <i>et al.</i> <sup>1</sup>	Bruce4	Mouse	Embryonic stem cells	
	Hematopoietic stem cell	Mouse	Bone marrow	Hematopoietic stem cell
	tissue cells	Mouse	Skin	(Fibroblasts, keratinocytes, epithelial cells)
Maher <i>et al.</i> <sup>36</sup>	HaCaT	Human	Skin	Keratinocyte cell
	2fTGH	Human	Skin	Keratinocyte cell
	B16	Mouse	Skin	Melanoma
	HuH-7.5	Human	Liver	Hepatoma, differentiated
Sommereyans <i>et al.</i> <sup>37</sup>	Muscle	Mouse	Muscle	
	Spleen	Mouse	Spleen	
	Spinal cord	Mouse	Spinal cord	
	Liver	Mouse	Liver	
	Kidney	Mouse	Kidney	
	Brain	Mouse	Brain	
	Heart	Mouse	Heart	
	Intestine	Mouse	Intestine	
	Stomach	Mouse	Stomach	
	Lung	Mouse	Lung	
	Epithelial	Mouse	Epithelial	
Endothelial	Mouse	Endothelial		
Zitzmann <i>et al.</i> <sup>38</sup>	BON1	Human	Pancreatic neuroendocrine tumor cells	

Lasfar <i>et al.</i> <sup>39</sup>	16-9	Hamster-human	Hamster-human somatic cell hybrid line	
	HT29	Human	Colon	Colorectal cancer-derived cell
	COS-1	African green monkey	Kidney	SV40 transformed African green monkey kidney
	CV-1	African green monkey	Kidney	Kidney, highly susceptible to SV40 infection
Numasaki <i>et al.</i> <sup>40</sup>	L929	Mouse	Connective tissue	Fibroblast like
	NIH 3T3	Mouse	Embryo	Fibroblast, contact inhibited
	B16	Mouse	Skin	Melanoma
	MCA205	Mouse	Lymphocyte	Fibrosarcoma cell
	B16	Mouse	Skin	Melanoma
Sato <i>et al.</i> <sup>41</sup>	Yac-1	Mouse	Lymphocyte	A lymphoma cell
	B16/F0	Mouse	Skin	Melanoma
	B16/F10	Mouse	Skin	Melanoma
	NIH3T3	Mouse	Embryo	Fibroblast, contact inhibited
	L929	Mouse	Connective tissue	Fibroblast
Wongthida <i>et al.</i> <sup>42</sup>	COS7	African green monkey	Kidney	Transformant of CV-1 cells by origin-defective SV-40
	B16(LIF)	Mouse	Skin	Melanoma
	B16ova	Mouse	Ovary	Melanoma cell
	BHK-21	Syrian hamster	Kidney	Subclone of BHK-21
Yoshimoto <i>et al.</i> <sup>43</sup>	SCCVII	Mouse	Skin	A murine squamous cell carcinoma cell
	C2C12	Mouse	Muscle	A myoblastoid cell
	B16	Mouse	Melanoma	Melanoma, skin, melanin pigment production (but large portion of cells is amelanotic) (C57BL/6 mouse)
	Bone marrow cells	Mouse	Bone marrow cells (C3H/He mice by flushing femurs with HANKS buffer)	

recently reported to be important for HCV infection by Vanwolleghem *et al.*,<sup>47</sup> who showed that 100% HCV infectivity was reached with high quality inocula in mice with human albumin levels of more than 1 mg/mL.

Spontaneous eradication of HCV has been reported to be higher in individuals with the rs12979860CC genotype.<sup>20</sup> In such individuals, components of both the innate and adaptive immune systems likely play a role in eliminating the invading virus in the absence of exogenous IFN. As no human or mouse adaptive immune effector cells are present in human hepatocyte chimeric mice, it is possible to isolate the effects of innate immunity in liver cells using this model. When liver cells are selected from donors with different *IL-28B* genotypes, the model provides an opportunity to study differences in innate immune responses associated with the *IL-28B* genotype.

Clonal infection with HCV genotypes 1a, 1b, 2a and 2b is now possible,<sup>48–50</sup> and reverse genetic approaches combining infectious HCV clones with the human hepatocyte chimeric mouse facilitate studying the effects of viral mutations and host factors, such as the *IL-28B* genotype, on infectivity of the virus. Several factors may influence infectivity of the virus, including serum lipid profile,<sup>51</sup> presence of neutralizing antibodies and presence of antibody-resistant viral quasispecies.<sup>52,53</sup> However, we found no difference in incidence of establishment of infection with genotype 1b clones among mice transplanted with different *IL-28B* genotype liver cells.<sup>54</sup> This result may derive from the specific infection route (intrahepatic injection of RNA to mouse liver) and the large RNA titers used in the study.

#### EXPRESSION OF INTERFERON-STIMULATED GENE (ISG) AND VIRAL LOAD IN HUMANS AND HUMAN HEPATOCYTE CHIMERIC MICE


ALTHOUGH THE MECHANISM underlying the *IL-28B* polymorphism remains unclear, a number of studies have reported that intrahepatic ISG expression levels are lower<sup>55–57</sup> and viral titers are higher<sup>8,12</sup> in patients with the eradication-favorable *IL-28B* genotype. Honda *et al.* showed that expression of a number of ISGs was higher in patients with the unfavorable rs8099917 TG or GG genotypes compared to those with the TT genotype and that non-responders were significantly over-represented among patients with high ISG expression levels.<sup>57</sup> Using paired liver biopsy samples, Sarasin-Filipowicz demonstrated that ISG expression levels in non-responders were initially higher prior to IFN treatment, but administration of IFN failed to induce ISG

expression levels above this baseline level, whereas IFN induced a strong upregulation of ISG expression in patients who achieved a rapid virological response.<sup>58</sup> Shebl *et al.* measured ISG expression levels in uninfected cells and found no evidence of an association with the *IL-28B* genotype, suggesting that the association observed in HCV-infected cells does not reflect normal expression levels in healthy cells and reflects the response to HCV infection.<sup>59</sup>

The chimeric mouse provides a suitable model to test hypotheses concerning the role of the *IL-28B* genotype on innate immune responses and ISG expression. Using this model, we found that ISG expression levels were also lower and viral titers were higher in human hepatocyte chimeric mice with the favorable *IL-28B* genotype.<sup>54</sup> As illustrated in Figure 1, the virus appears to replicate more efficiently in mice with the favorable genotype, perhaps because whenever the viral load is low hepatocytes with the favorable genotype can efficiently clear the virus so that chronic infection only results under higher viral loads.<sup>20,60</sup> At the same time, ISG expression is lower in cells with the favorable allele, which may be advantageous by preventing saturation of the IFN signaling pathway through continual stimulation.<sup>58</sup> However, earlier reports demonstrated that induction of a strong response to IFN- $\alpha$  is dependent on a weak constitutive IFN signal to maintain IFN-dependent expression of insulin-related factor-7, an essential transcription factor involved in IFN signal transduction that has a short half-life.<sup>61</sup> The unfavorable *IL-28B* genotype might alter the balance of this feedback loop in the presence of HCV. Although we observed that ISG expression levels were lower in mice with the favorable genotype prior to IFN treatment (unpubl. data, K. Chayama, Hiroshima University, Japan), ISG expression increased sharply following IFN administration in mice with the favorable genotype and were significantly higher than in mice with an unfavorable genotype.<sup>54</sup>

#### ISG EXPRESSION LEVELS AND EFFECT OF IFN THERAPY IN HUMANS AND CHIMERIC MICE

PRETREATMENT ISG EXPRESSION levels may be a stronger predictor of outcome of combination therapy than the *IL-28B* genotype,<sup>62</sup> suggesting that the mechanism of the SNP is related to its role in ISG regulation. Lower ISG expression levels are associated with the eradication-favorable *IL-28B* genotype in chronic hepatitis C patients,<sup>55–57</sup> and high baseline expression levels of ISG such as *RIG-I*, *ISG-15* and *USP-18* correlate with poor response to therapy.<sup>63</sup> Using the human



**Figure 1** Hypothetical model of virus replication in hepatocytes with eradication-favorable (interleukin [IL]-28B rs12979860 CC or rs8099917 TT) or unfavorable (rs12979860 CT/TT or rs8099917 GT/GG) genotypes. HCV may be eliminated from individuals with the favorable genotype at low titer but may persistently infect those with high titers or the unfavorable genotype (upper right and left panels). Viral sensors continuously detect viral RNA during chronic infection (central panel), resulting in continuous activation of interferon-stimulated genes (ISG), including interferon inhibitory molecules such as *PIAS* and *SOCS3*. In hepatocytes with the unfavorable genotype, ISG expression may be refractory to further interferon stimulation, resulting in a poor response to therapy, but in hepatocytes with the favorable genotype, low baseline ISG expression may prevent overexpression of interferon signal inhibitors, resulting in stronger ISG induction and a better response to therapy.

hepatocyte chimeric mouse model, we showed that intrahepatic expression levels were significantly higher and HCV RNA reduction was significantly greater in mice with rs12979860CC hepatocytes following IFN administration.<sup>54</sup> Several genes that suppress IFN-dependent antiviral activity, such as *PIAS* and genes in the *SOCS* family, are themselves ISGs, and may serve as a negative feedback loop to regulate IFN signaling. Consequently, continuous low-level ISG expression in hepatocytes with the unfavorable genotype may dampen IFN sensitivity and prevent effective ISG induction when IFN is administered during treatment.

### RELATIONSHIP BETWEEN *IL-28B* GENOTYPE AND HCV CORE AMINO ACID SUBSTITUTIONS

**R**EVERSE GENETICS USING the chimeric mouse model could facilitate detailed studies of the effect of host and viral factors on IFN sensitivity and ISG expression. HCV core protein substitutions are predictive of outcome of peginterferon plus ribavirin combination therapy,<sup>64,65</sup> and patients with the unfavorable *IL-28B* genotype are more likely to host viruses having core substitutions.<sup>66</sup> To examine these interactions *in*